II. Epidemiology
- Common cause of Vision Loss in older adults
- However, also common in young adults (one third of cases in age <45 years old)
- Contrast with Central Retinal Artery Occlusion in older adults
III. Pathophysiology
- Venous Occlusion results in Retinal edema, Hemorrhage and vascular leak
- Venous Thromboembolism may result from vessel damage or Hypercoagulable state
IV. Risk Factors
- Hypercoagulable State
- Age over 55 years
- Hypertension
- Hyperlipidemia
- Diabetes Mellitus
- Tobacco Abuse
V. Types
- Nonischemic Central Retinal Vein Occlusion (75% of cases)
- Progresses to ischemic types in 15% of patients within 4 months (34% within 3 years)
- Sudden painless, unilateral visual blurring (better than 20/200)
- Mild funduscopic findings
- No Relative Afferent Pupillary Defect
- Ischemic Central Retinal Vein Occlusion
- Sudden painless, severe unilateral visual loss (worse than 20/200)
- Relative Afferent Pupillary Defect
- Marked funduscopic changes
VI. Symptoms
- Monocular painless visual loss
- May initially present with transient episodes of mild Blurred Vision
VII. Signs
- Decreased Visual Acuity
- Afferent Pupillary Defect may be present (esp. ischemic CRVO)
-
Funduscopic Exam
- Retinal veins dilated and tortuous
- Blood streaked Retina or flame-shaped Hemorrhages (esp. in ischemic type)
- Diffuse Retinal Hemorrhages radiating from optic disc ("Blood and thunder Retina")
- Cotton wool patches may be present (esp. with Hypertension)
VIII. Differential Diagnosis
IX. Management
- Urgent Ophthalmology Consultation
- Antivascular endothelial growth factors
- Corticosteroids
- Photocoagulation (if neovascularization)
- No specific management to alter Hemorrhages
- Management is focused on reducing longerterm complications of Retinopathy including Glaucoma
- Non-urgent laser photocoagulation may be needed in some cases
- Management is also focused on reducing risk of disease progression
- Optimize management of Hypertension and Diabetes Mellitus
- Optimize hydration
- Decrease Intraocular Pressure (e.g. Acetazolamide)
-
Patient Instructions
- Return immediately for Decreased Visual Acuity
- Follow-up after initial ophthalmology evaluations
- Follow-up ophthalmology in 3 months (monthly for at least 6 months if ischemic CRVO)
X. Prognosis
- For those who do not convert to ischemic CRVO, 50% will recover nearly normal Vision
XI. Complications
XII. References
- Hartmann (2016) Crit Dec Emerg Med 30(6): 3-11
- Sales, Patel and Patel (2019) Crit Dec Emerg Med 33(12): 3-13